Artelo Biosciences
ARTL
8 hedge funds and large institutions have $76.4K invested in Artelo Biosciences in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
33% more funds holding
Funds holding: 6 → 8 (+2)
0.02% more ownership
Funds ownership: 0.08% → 0.1% (+0.02%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
3% less capital invested
Capital invested by funds: $78.4K → $76.4K (-$2.01K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
+$56.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$11.3K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$200 |
| 4 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$133 |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$33 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Advisers
New York
|
-$40.9K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.67K |
| 3 |
JP Morgan Chase
New York
|
-$611 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
HF
1
HRT Financial
New York
| $44K | +$56.1K | +1,682 | New |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $28.9K | +$11.3K | +338 | +44% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $3.13K | -$4.67K | -140 | -54% |
|
|
4
UBS Group
Zurich,
Switzerland
| $164 | +$200 | +6 | New |
|
|
5
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| $104 | +$133 | +4 | New |
|
6
Wells Fargo
San Francisco,
California
| $31 | – | – | – |
|
7
Morgan Stanley
New York
| $29 | – | – | – |
|
|
8
Fidelity Investments
Boston,
Massachusetts
| $29 | +$33 | +1 | New |
|
|
9
Two Sigma Advisers
New York
| – | -$40.9K | -1,142 | Closed |
|
|
10
JP Morgan Chase
New York
| – | -$611 | -17 | Closed |
|
ARTL Hedge Fund Activity: Q3 2023 in Review
8 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q3 2023, worth a combined $76.4K — down 2.6% from $78.4K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new ARTL positions and 2 closed out — a net gain of 2 holders — while 1 added to existing stakes and 1 trimmed.
The largest buyer was HRT Financial, opening a new position worth an estimated $56.1K. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $40.9K sold.
- 8 institutional investors held Artelo Biosciences (ARTL) as of Q3 2023, up from 6 in Q2 2023.
- Funds reported $76.4K of Artelo Biosciences stock for Q3 2023, down 2.6% quarter-over-quarter.
- 4 funds opened new Artelo Biosciences positions in Q3 2023 and 2 closed out, a net change of +2 holders.
- The largest Artelo Biosciences buyer in Q3 2023 was HRT Financial, an estimated $56.1K added.
- The largest Artelo Biosciences seller in Q3 2023 was Two Sigma Advisers, an estimated $40.9K sold.
Based on aggregated 13F filings for Q3 2023.